PPIs in Morocco: Raciper, Inexium, Inipomp — reflux guide 2026

Gastro-oesophageal reflux disease is one of the most frequent reasons for general practice consultations in Morocco. Proton pump inhibitors (PPIs) — esomeprazole, omeprazole, pantoprazole, lansoprazole and rabeprazole — have constituted the reference pharmacological response for nearly three decades. On the Moroccan market, three brands dominate: Raciper, Inexium and Inipomp.

This guide, reviewed by Dr Omar Chaabi, gastroenterologist at Ibn Sina University Hospital in Rabat, summarises updated 2026 practice.

01GORD: recognising the real symptoms#

Gastro-oesophageal reflux disease (GORD) becomes pathological when episodes occur more than twice a week or are accompanied by lesions of the oesophageal mucosa. The prevalence of chronic GORD in the Maghreb and Mediterranean countries is estimated between 15 and 20% of the adult population, considerably higher than northern Europe.

Typical symptoms combine heartburn (pyrosis) and acid regurgitation in the mouth, particularly at night when lying down. The clinical picture can broaden to atypical symptoms: chronic nocturnal cough, morning hoarseness, paradoxical asthma, pseudo-anginal chest pain, and dental erosions often noticed by the dentist before the patient.

Alarm signs that demand prompt endoscopy are progressive dysphagia, unexplained weight loss, anaemia, repeated vomiting, or digestive bleeding. In any Moroccan patient over 50 presenting with recent-onset reflux, endoscopy is recommended from the outset (ACG 2022 guidelines).

02How PPIs act#

PPIs are prodrugs: swallowed as gastro-resistant tablets, they are absorbed in the small intestine, then activated in the secretory canaliculi of parietal cells where they bind covalently to the H+/K+ ATPase (proton pump), blocking acid secretion until the cell synthesises new pumps — a process taking 24 to 48 hours.

Onset is not immediate: a PPI taken this morning reaches peak efficacy after 3 to 5 days, with a stable plateau of acid inhibition observed between day 5 and day 7 once the pool of proton pumps is fully saturated. This pharmacodynamic profile explains why a patient who interrupts treatment after 48 hours because "he felt nothing" will wrongly conclude the drug is ineffective: the clinical evaluation window must always exceed a full week. An alginate such as Gaviscon or an antacid such as Maalox remains useful as adjunct therapy in the first days to relieve symptoms while the efficacy curve reaches its plateau.

The pharmacological distinctiveness of PPIs rests on their status as pH-dependent activated prodrugs. The molecule circulates in inactive form in plasma at neutral pH, crosses the parietal cell membrane, then concentrates exclusively in the secretory canaliculi where pH drops to 1-2. In this highly acidic micro-environment the prodrug undergoes protonation, transforms into an active sulphenamide and binds irreversibly to cysteine residues of the H+/K+ ATPase pump. This selective activation in acid-secreting cells alone explains the excellent tolerability compared with H2-blockers, which act on ubiquitous receptors throughout the body.

The class comprises five molecules available in Morocco: omeprazole (Mopral AstraZeneca + generics), esomeprazole (Inexium AstraZeneca, generic Raciper from Sothema), pantoprazole (Inipomp Sanofi), lansoprazole (Lanzor) and rabeprazole (Pariet).

03Raciper, Inexium, Inipomp: which to choose?#

Raciper, manufactured by Sothema in Bouskoura near Casablanca, contains esomeprazole. It is bioequivalent to the originator Inexium from AstraZeneca.

For uncomplicated GORD, omeprazole 20 mg or pantoprazole 20 mg remain the most cost-effective options. For erosive oesophagitis grade C or D on the Los Angeles classification, esomeprazole 40 mg (Raciper 40 or Inexium 40) benefits from slightly superior healing data at 8 weeks, around 92% versus 86% (meta-analysis by Gralnek et al., 2006).

When the patient is on clopidogrel (Plavix), omeprazole and esomeprazole potently inhibit CYP2C19, the enzyme essential for clopidogrel bio-activation. The FDA issued a black box warning in 2009 advising against the omeprazole/esomeprazole + clopidogrel combination. Pantoprazole (Inipomp) therefore remains the preferred PPI in patients on antiplatelet therapy after coronary stenting.

04Dosing: 20 mg or 40 mg, when?#

The golden rule: take the tablet 30 to 60 minutes before the first meal of the day. Proton pumps are only activated when the parietal cell is stimulated by the arrival of food. Taking a PPI with food or in the evening reduces efficacy by roughly 30 to 50%, a very common mistake in Moroccan pharmacy practice.

For uncomplicated GORD in adults, the standard dose is 20 mg once daily for 4 to 8 weeks. Erosive oesophagitis grade C/D warrants 40 mg in the morning for 8 weeks from the start, extendable to 12 weeks if endoscopic healing fails.

For *Helicobacter pylori eradication, a bacterium present in 70 to 80% of Moroccan adults according to epidemiological studies conducted at Ibn Rochd University Hospital in Casablanca and Hassan II University Hospital in Fez, the Maastricht VI/Florence consensus (2022) recommends, in regions of clarithromycin resistance exceeding 15-20% — which is the case in Morocco — a bismuth quadruple therapy as first-line: standard-dose PPI twice daily + bismuth subcitrate + tetracycline + metronidazole for 10 to 14 days. The historical classic triple therapy combining PPI + amoxicillin 1 g morning and evening + clarithromycin 500 mg morning and evening for 14 days retains its place where resistance is documented or presumed low, typically in patients without recent macrolide exposure. Eradication rates at 12 weeks, verified by urea breath test or stool antigen detection, must reach at least 85% for a regimen to be deemed acceptable. In Morocco, the cost of a 14-day bismuth quadruple therapy ranges between 350 and 500 MAD all medications included, compared with 180 to 280 MAD* for classic triple therapy.

In children, omeprazole has European authorisation from 1 year: 10 mg/day for 10-20 kg, 20 mg/day above. No PPI has an over-the-counter indication in children and medical prescription is mandatory.

In pregnant women, omeprazole is the reference PPI. The large Danish cohort (Pasternak and Hviid, NEJM 2010) covering over 5,000 pregnancies exposed to a PPI in the first trimester found no significant increase in malformation risk.

Contraindications and major interactions

• High-dose methotrexate: combination contraindicated.
• Atazanavir and nelfinavir: combination contraindicated.
• Ketoconazole, itraconazole, posaconazole: reduced absorption.
• Digoxin, tacrolimus: monitoring required.
• Warfarin and vitamin K antagonists: possible INR modification.

In case of overdose, there is no specific antidote; haemodialysis is ineffective because PPIs are strongly bound to plasma proteins. Contact the Moroccan Anti-Poison Centre.

05Treatment duration and deprescribing#

PPIs have become one of the most overconsumed drug classes worldwide. The fundamental clinical rule: a PPI must be prescribed at the minimum effective dose for the shortest possible duration.

For occasional or moderate GORD without oesophagitis, 4 to 8 weeks suffice in 70% of cases. Erosive oesophagitis generally needs 8 weeks. Only three situations justify long-term use: histologically confirmed Barrett's oesophagus, prevention of recurrent ulcers in patients on chronic NSAIDs, and Zollinger-Ellison syndrome.

Deprescribing is delicate. Abrupt discontinuation of a PPI taken for more than eight weeks provokes acid rebound linked to hypergastrinaemia: chronic acid suppression has stimulated compensatory gastrin secretion by the antrum, and this accumulated gastrin triggers, on abrupt PPI cessation, a transient acid hypersecretion that can last 2 to 6 weeks and which the patient wrongly interprets as proof that he "cannot do without" the treatment. The clinical strategy rests on the stepwise rule: never stop a PPI abruptly after more than 8 weeks of use, but wean progressively by reducing the dose by 50% over 4 weeks (switch from 40 to 20 mg, or from 20 to 10 mg by opening the omeprazole capsule), then by spacing to every other day over an additional 2 to 4 weeks, and only then move to "on-demand" dosing exclusively at symptom recurrence. Gaviscon or an H2-blocker such as famotidine can cover symptom peaks during this transition phase.

The Cochrane review by Boghossian et al. (2017) showed that around 26 to 29% of patients remain symptom-free at 6 months after complete discontinuation, an encouraging figure that justifies systematically proposing a weaning attempt to any patient on PPI for more than a year without formal indication. The Canadian recommendations by Farrell et al. (2017), adopted by HAS, propose a deprescribing algorithm now widely used in Moroccan general practice, particularly in pilot programmes by CNOPS for retirees on polypharmacy.

06Adverse effects and long-term risks#

In the short term, PPIs are among the best-tolerated medications. The most commonly reported side effects — headache, mild nausea, transient diarrhoea, bloating — affect less than 5% of patients and generally resolve within a few days without requiring discontinuation.

Beyond one year of continuous treatment, the risk profile shifts and several warning signals have emerged in the literature. Vitamin B12 deficiency occurs in approximately 10% of patients after 2 years, as gastric acid is necessary to release dietary cobalamin from its transport proteins; annual measurement is reasonable beyond 18 months of treatment, especially in the elderly. Hypomagnesaemia affects 2-3% of long-term users, sometimes symptomatic as cramps, tetany or cardiac arrhythmias, and warrants ionic monitoring if diuretics are co-prescribed. The risk of osteoporosis and fractures of the hip, wrist and spine was established by the Yang cohort (JAMA 2006, OR 1.44 after 1 year, 2.65 after 7 years), likely linked to impaired calcium absorption from chronic hypochlorhydria.

On the infectious side, community-acquired pneumonia and especially *digestive infections with Clostridioides difficile** are significantly more frequent on PPIs, with the FDA having issued a safety communication* in 2012 to alert on this risk. The gastric acid barrier serves as a primary antimicrobial filter that the PPI removes.

The dementia controversy, fuelled by the German study by Gomm et al. (JAMA Neurol 2016) suggesting a 44% increased risk in chronic users over 75, has since been largely qualified by more rigorous meta-analyses (notably Khan et al. 2020) that did not confirm a causal association after adjusting for comorbidities. Dr Chaabi recalls that the observed correlation mainly reflects polypharmacy and overall frailty of the elderly patient, not a specific effect of the molecule.

07Prices and AMO reimbursement in Morocco#

A pack of 14 generic omeprazole tablets: 30 to 55 MAD, generic pantoprazole 45 to 85 MAD, esomeprazole Raciper 45 to 85 MAD depending on dosage, while the originators Inexium and Pariet often exceed 150 MAD. Over 8 weeks, the gap between generic and originator can represent 300 to 600 MAD of savings for a Moroccan household.

Reimbursement by AMO follows the Reference Tariff (TR) published by ANAM. PPIs are reimbursed at 70% of TR for both CNSS and CNOPS schemes.

08Alternatives: antacids, alginates and H2-blockers#

Strict antacids — Maalox suspension with aluminium and magnesium hydroxide, Phosphalugel with aluminium phosphate, Rennie with calcium and magnesium carbonate — act by rapid chemical neutralisation of gastric contents. Their effect appears in under 5 minutes but lasts only 1 to 2 hours, making them ideal rescue medications between meals or for occasional post-prandial heartburn. The liquid suspension form is generally more effective than chewable tablets as it coats the oesophageal mucosa more quickly.

Alginates (Gaviscon, Topaal) constitute a separate class: on contact with gastric acid, sodium alginate forms a viscous raft that floats on stomach contents and mechanically obstructs the cardia, physically preventing reflux of acid contents. Gaviscon Advance, available in Moroccan pharmacies, is particularly indicated for nocturnal regurgitation and pregnancy reflux where it has an excellent evidence base.

H2-blockers such as famotidine (Pepcidine, Famotac) partially inhibit acid secretion by blocking the H2 histamine receptor on the parietal cell surface. Their efficacy is lower than PPIs — acid reduction of 60-70% versus 90-95% — but their onset is faster (30 to 60 minutes) and they remain useful as second-line in PPI-intolerant patients or as occasional evening adjunct during weaning. Note that ranitidine (Raniplex, Zantac), long the class leader, was withdrawn worldwide in 2020 after the FDA and EMA discovered time- and heat-dependent formation of N-nitrosodimethylamine (NDMA), a probable carcinogen per IARC classification. In Morocco, the DMP (Directorate of Drugs and Pharmacy) relayed this marketing authorisation suspension, and famotidine has definitively replaced ranitidine in all prescriptions.

But no medication replaces lifestyle measures: raise the head of the bed by 15-20 cm (with a wedge under the mattress, not extra pillows that bend the neck), avoid meals within 3 hours of bedtime, limit fats, alcohol, coffee, strong tea, carbonated drinks, chocolate and mint, split meals into 4 to 5 light intakes rather than 2 heavy ones, stop smoking and lose weight if BMI exceeds 27 — effective in 60 to 70% of patients and the only truly curative long-term treatment, particularly relevant to the Ramadan context where the condensed eating rhythm mechanically increases reflux episodes.

09When to consult a gastroenterologist#

Consultation with a gastroenterologist becomes necessary in: patients over 50 with recent-onset reflux, persistence of symptoms after 8 weeks of PPI, alarm signs, or wish to deprescribe a treatment lasting more than a year.

Upper gastrointestinal endoscopy costs between 800 and 1,500 MAD in private practice, partially reimbursed by AMO, and free in university hospitals for RAMED/Tadamon patients.

This article is for informational purposes only and does not replace personalised medical consultation.